

# CITATION REPORT

List of articles citing

## Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review

DOI: 10.7326/m20-2496

Annals of Internal Medicine, 2020, 173, 287-296.

**Source:** <https://exaly.com/paper-pdf/75787173/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
160	Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. <b>2020</b> , 7, ofaa446		34
159	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. <b>2020</b> , 49, 763-773		13
158	Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action. <b>2020</b> , 262, 118493		24
157	"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey". <b>2020</b> , 14, 1413-1418		2
156	Mining the past to treat the present, ever mindful of the future: Low-dose radiotherapy and COVID-19 pneumonia. <b>2020</b> , 126, 5017-5021		3
155	Early management of critically ill patients with COVID-19. <b>2020</b> , 1, 1418-1426		0
154	[Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia]. <b>2020</b> , 73, 964-966		
153	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. <b>2020</b> , 56, 106056		18
152	Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. <b>2020</b> , 257, 118096		24
151	Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, W128-W129	8	12
150	Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, W88-W89	8	9
149	Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, W156-W157	8	17
148	Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, W48-W51	8	8
147	Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, W78-W79	8	15
146	Does hydroxychloroquine reduce mortality for COVID-19?. <b>2020</b> , 82, 21-22		2
145	Coronavirus Infection of the Central Nervous System: Animal Models in the Time of COVID-19. <b>2020</b> , 7, 584673		2
144	Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic. <b>2020</b> , 85, 102481		5

143	Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. <b>2020</b> , 2, e603-e612		173
142	Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?. <b>2020</b> , 12, 1139-1144		1
141	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. <b>2020</b> , 11, 1124		41
140	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. <b>2020</b> , 19, 40		62
139	Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). <b>2020</b> , 7, 41		37
138	Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239644	3-7	10
137	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. <b>2020</b> , 2, e689-e697		29
136	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). <b>2020</b> , 13, 1023-1033		6
135	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <b>2020</b> , 82, 38-47		64
134	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. <b>2020</b> , 57, 4856-4877		20
133	Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases. <b>2020</b> , 40, 597-601		6
132	Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome. <b>2020</b> , 2020, 8829309		3
131	Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. <i>BMJ Open</i> , <b>2020</b> , 10, e041577	3	12
130	Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. <i>Microorganisms</i> , <b>2020</b> , 8,	4-9	26
129	An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. <b>2020</b> , 37, 101755		104
128	Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. <b>2020</b> , 383, 585-586		65
127	Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. <b>2020</b> , 6,		12
126	Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli. <b>2021</b> , 80, e76		1

125	Adverse events associated with potential drugs for COVID-19: a case study from real-world data. <b>2021</b> , 22, 1232-1238	3
124	Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug. <b>2021</b> , 47, 570-575	1
123	Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. <b>2021</b> , 3, e19-e27	28
122	A district-level susceptibility and vulnerability assessment of the COVID-19 pandemic's footprint in India. <b>2021</b> , 36, 100390	7
121	Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. <b>2021</b> , 73, 48-52	5
120	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. <b>2021</b> , 76, 30-42	70
119	Weekly updates of national living evidence-based guidelines: methods for the Australian living guidelines for care of people with COVID-19. <b>2021</b> , 131, 11-21	9
118	Review of registered clinical trials for the treatment of COVID-19. <b>2021</b> , 82, 474-493	14
117	[Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine]. <b>2021</b> , 156, 166-171	0
116	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <b>2021</b> , 17, 11-30	293
115	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. <b>2021</b> , 7, 1389-1408	39
114	Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania. <b>2021</b> , 43, 49-57	14
113	COVID-19 prevalence among health-care workers of Gastroenterology department: An audit from a tertiary-care hospital in India. <b>2021</b> , 5, 56-63	4
112	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. <b>2021</b> , 134, 166-175	7
111	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. <b>2021</b> , 181, 195-202	102
110	Has the door closed on hydroxychloroquine for SARS-COV-2?. <b>2021</b> , 27, 3-5	3
109	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <b>2021</b> , 59, 12-23	24
108	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. <b>2021</b> , 394, 775-782	10

107	The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm. <b>2021</b> , 73, 23-35	27
106	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. <b>2021</b> , 27, 19-27	144
105	Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. <b>2021</b> , 166, 949-954	65
104	Ivermectin in the Prophylaxis and Treatment of Patients with SARS-CoV-2: A Living Systematic Review and Meta-Analysis.	
103	A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. <b>2021</b> , 93, 2705-2721	5
102	Methodological quality of COVID-19 clinical research. <b>2021</b> , 12, 943	30
101	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <b>2021</b> , 2, CD013587	57
100	Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine. <b>2021</b> , 156, 166-171	1
99	Balancing clinical evidence in the context of a pandemic. <b>2021</b> , 39, 270-274	1
98	Utility of the antigen test for coronavirus disease 2019: Factors influencing the prediction of the possibility of disease transmission. <b>2021</b> , 104, 65-72	8
97	Care for Patients With Neuromuscular Disorders in the COVID-19 Pandemic Era. <b>2021</b> , 12, 607790	5
96	No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19. <b>2021</b> , 104, 34-40	4
95	The Organoid Platform: Promises and Challenges as Tools in the Fight against COVID-19. <b>2021</b> , 16, 412-418	11
94	Risk factors for mortality in hospitalized patients with COVID-19 from three hospitals in Peru: a retrospective cohort study. <b>2021</b> , 10, 224	6
93	COVID-19, hydroxychloroquine and the importance of disease progression. <b>2021</b> , 10, 299-311	1
92	QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19. <b>2021</b> , 46, 800-806	2
91	Diabetes mellitus in combination with COVID-19: modern views on therapy. <b>2021</b> , 8-20	
90	COVID-19 in Children: Respiratory Involvement and Some Differences With the Adults. <b>2021</b> , 9, 622240	4

89	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. <b>2021</b> , 19, 1331-1339		2
88	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <b>2021</b> , 12, 2349		83
87	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <b>2021</b> , 80, 712-723		12
86	Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages. <b>2021</b> , 7, 24		33
85	COVID-19-The American Perspective. <b>2021</b> , 39, 424-429		0
84	Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis. <b>2021</b> , 12, 649472		6
83	Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19. <b>2021</b> , 10, 200-210		1
82	Impact of COVID-19 in Liver Disease Progression. <b>2021</b> , 5, 1138-1150		15
81	Advancing lung organoids for COVID-19 research. <b>2021</b> , 14,		18
80	COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. <b>2021</b> , 9, 760-768		1
79	Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
78	Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomised, controlled, multicentric clinical trial.		3
77	Efficacy and Safety of Hydroxychloroquine for Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
76	Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. <b>2021</b> , 190, 2405-2419		4
75	Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study. <b>2021</b> , 12, 700776		0
74	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. <b>2021</b> , 9,		9
73	Analysis of COVID-19 Guideline Quality and Change of Recommendations: A Systematic Review. <b>2021</b> , 2021, 1-22		0
72	COVID-19 Associated Rhino-Orbital Mucormycosis Complicated by Gangrenous and Bone Necrosis-A Case Report from Honduras. <b>2021</b> , 9,		1

71	Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. <b>2021</b> , 19, 317-326		5
70	G6PD distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19. <b>2021</b> , 21, 649-656		1
69	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. <i>The Lancet Regional Health Americas</i> , <b>2021</b> , 2, 100062		9
68	Does hydroxychloroquine reduce mortality in patients with COVID-19? A meta-analysis with trial sequential analysis. <b>2021</b> , 75, e14448		0
67	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. <b>2021</b> , 43, 102135		4
66	Anthraquinolone and quinolizine derivatives as an alley of future treatment for COVID-19: an in silico machine learning hypothesis. <b>2021</b> , 11, 17915		0
65	Impact of Coronavirus Diseases on Liver Enzymes. <b>2021</b> , 13, e17650		0
64	Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: A concept paper. <b>2021</b> , 141, 82-89		1
63	Association Between Caseload Surge and COVID-19 Survival in 558 U.S. Hospitals, March to August 2020. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1240-1251	8	35
62	Drugs for the Treatment of COVID-19. <b>2021</b> , 193-204		
61	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. <b>2021</b> , 2, 1		6
60	Epidemiology of COVID-19 in Latin America. <b>2021</b> , 11-24		
59	Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. <i>Phytotherapy Research</i> , <b>2021</b> , 35, 3013-3031	6.7	28
58	Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , <b>2020</b> , 17, 41-48	8.1	2
57	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2020</b> ,	0.9	2
56	Therapeutics for COVID-19: established and in development. <i>Microbiology Australia</i> , <b>2020</b> , 41, 217	0.8	2
55	Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges. <i>Expert Opinion on Drug Discovery</i> , <b>2021</b> , 16, 365-371	6.2	3
54	The Efficacy of IL-6 Inhibitor Tocilizumab in Reducing Severe COVID-19 Mortality: A Systematic Review.		7

53	Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials.		3
52	Therapeutic interventions for COVID-19: a living overview of reviews. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2020</b> , 14, 1753466620976021	4.9	3
51	[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "Bromhexine and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT)". <i>Kardiologiya</i> , <b>2020</b> , 60, 4-15	1.5	7
50	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 18,	4.6	7
49	The Role of Methemoglobin and Carboxyhemoglobin in COVID-19: A Review. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 10,	5.1	7
48	Therapeutic status of hydroxychloroquine in COVID-19: A review. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , <b>2020</b> , 36, S160-S165	1.3	4
47	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review. <i>PeerJ</i> , <b>2020</b> , 8, e10322	3.1	25
46	Integrating heterogeneous data to facilitate COVID-19 drug repurposing. <i>Drug Discovery Today</i> , <b>2021</b> , 27, 558-558	8.8	2
45	COVID-19 and the medicines regulation challenges in times of pandemic. <i>Ciencia E Saude Coletiva</i> , <b>2021</b> , 26, 4693-4702	2.2	0
44	Current treatment strategies for COVID-19 (Review). <i>Molecular Medicine Reports</i> , <b>2021</b> , 24,	2.9	2
43	Combating Oxidative Stress and Inflammation in COVID-19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2021</b> , 2021, 5513868	6.7	16
42	Rheumatoid Arthritis in the Era of COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , <b>2020</b> , 31, 257-258	1.4	0
41	QUM and COVID-19 in young adults. <i>Australian Prescriber</i> , <b>2020</b> , 43, 110	1.4	
40	COVID-19: risk factors for severe cases of the Delta variant. <i>Aging</i> , <b>2021</b> , 13, 23459-23470	5.6	5
39	Progress in the risk assessment of hydroxychloroquine in frail elderly people. <i>Aging Medicine (Milton (N S W))</i> , <b>2021</b> , 4, 53-57	3.5	
38	Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India. <i>Journal of Public Health Research</i> , <b>2020</b> , 9, 1888	2.2	
37	Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis. <i>Kliniceskaa Mikrobiologia I Antimikrobnaa Himioterapia</i> , <b>2020</b> , 22, 164-174	1.3	
36	Antiviral therapy of COVID-19. <i>Scripta Medica</i> , <b>2020</b> , 51, 131-133	0.3	3



35	Prophylactic use of hydroxychloroquine among healthcare workers in a case-control study. <i>Indian Journal of Medical Research</i> , <b>2020</b> , 152, 127-128	2.9	0
34	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis.		1
33	Methodological Rigor in COVID-19 Clinical Research [A Systematic Review and Case-Control Analysis.		1
32	Pediatric Hematopoietic Stem Cell Transplant in the COVID-19 Pandemic: The Problems We Faced and The Strategies We Adopted. <i>Archives of Pediatric Infectious Diseases</i> , <b>2020</b> , 8,	1.4	
31	Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study.		
30	Jeopardy of COVID-19: Rechecking the Perks of Phytotherapeutic Interventions. <i>Molecules</i> , <b>2021</b> , 26,	4.8	0
29	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. <i>Future Microbiology</i> , <b>2021</b> , 16, 1341-1370	13.0	9
28	Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , <b>2021</b> , 47, e20210236	1.1	0
27	Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0261843	3.7	0
26	E-cigarette or Vaping product use Associated Lung Injury (EVALI) in the time of COVID-19: A clinical dilemma.. <i>Pediatric Pulmonology</i> , <b>2021</b> ,	3.5	0
25	The Australian living guidelines for the clinical care of people with COVID-19: What worked, what didn't and why, a mixed methods process evaluation.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0261479	3.7	0
24	Hydroxychloroquine for COVID-19: Variation in Regional Political Preferences Predicted New Prescriptions after President Trump's Endorsement.. <i>Journal of Health Politics, Policy and Law</i> , <b>2022</b> ,	2.6	0
23	The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.. <i>Brazilian Journal of Infectious Diseases</i> , <b>2022</b> , 102328	2.8	0
22	COVID-19 and Influenza: Differences, Similarities, and Coinfection. <i>Archives of Pediatric Infectious Diseases</i> , <b>2022</b> , In Press,	1.4	0
21	Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.. <i>BMJ Open</i> , <b>2022</b> , 12, e048502	3	3
20	Recent Advancements on COVID-19: A Comprehensive Review.. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 10351-10372	2.3	2
19	Remote selective decarboxylative difluoroarylmethylation of 8-aminoquinolines under transition metal-free conditions. <i>Organic Chemistry Frontiers</i> ,	5.2	0
18	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , <b>2022</b> , 40, 289-295	0.1	

17	Prophylactic use of hydroxychloroquine (HCQS) in COVID-19: A questionnaire-based study in health care professionals. <i>Annals of African Medicine</i> , <b>2022</b> , 21, 113	1.7	
16	Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. <i>Microorganisms</i> , <b>2022</b> , 10, 1284	4.9	1
15	Therapeutic Interventions Implemented During the First Year of the COVID-19 Pandemic: A Systematic Review of Evidence. <i>Cyprus Journal of Medical Sciences</i> , <b>2022</b> , 7, 287-302	0.9	
14	An Executed Plan to Combat COVID-19 in the United States. <i>Advances in Anesthesia</i> , <b>2022</b> ,	0.6	
13	Evidence in decision-making in the context of COVID-19 in Latin America. <i>The Lancet Regional Health Americas</i> , <b>2022</b> , 14, 100322		
12	Characteristics of Living Systematic Review for COVID-19. Volume 14, 925-935		
11	Hydrolysis improves the inhibition efficacy of bovine lactoferrin against infection by SARS-CoV-2 pseudovirus. <b>2022</b> , 105488		1
10	Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: An overview. 9,		0
9	As implicações bioéticas da Comissão Parlamentar de Inquérito da Pandemia: o caso Prevent Senior. <b>2022</b> , 11, 52-66		0
8	Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects. <b>2022</b> , 12, 2047		0
7	The Myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19 is far from reality. <b>2023</b> , 13,		0
6	Liver dysfunction-related COVID-19: A narrative review. 11, 5-17		0
5	COVID-19: Diabetes Perspective Pathophysiology and Management. <b>2023</b> , 12, 184		1
4	Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial. <b>2023</b> , 16,		0
3	Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care. <b>2023</b> , 11, 790		0
2	Unconventional Products for COVID-19 Prevention: Practices, Experiences and Perceptions of Frontline Workers in Borno State, Nigeria.		0
1	Terapi Sel Punca dan Tata Laksana Covid-19. <b>2023</b> , 36, 11-19		0